Appoints senior Histopathologist Dr Jay Mehta, President & Head, Neuberg Oncopath
Neuberg Diagnostics, one of the top 4 Pathology laboratory chains in India, with more than 150 labs and 2000+ collection centres and having a presence in India, South Africa, the UAE and the US, launched Neuberg Oncopathology Reference Laboratory, a state-of-the-art second opinion Oncopathology laboratory in Mumbai. The lab was inaugurated by Dr GSK Velu, CMD, Dr Sandip Shah, Executive Director, Neuberg Diagnostics and Dr Jay Mehta, President & Head, Neuberg Oncopath.
The centre will pave way for advanced cancer care diagnosis, with experienced Oncopathologists, and geneticists, and will house all modern technologies and technical infrastructure, to deliver better diagnostic insights to oncologists across the country and improve the quality of life for cancer patients.
The newly established Neuberg Oncopathology lab, which is located at Vidyavihar, Mumbai, Maharashtra will be headed by Dr Jay Mehta, President & Head, of Neuberg Oncopath. Dr Mehta is a senior Surgical Pathologist, specialising in Oncopathology, with over 20 years of clinical experience. He completed his post-graduation from the renowned Tata Memorial Hospital, Mumbai. Besides oncopathology in general, he has a special interest in Lymphomas, Bone marrow pathology, Gastrointestinal tumours, and Soft tissue sarcomas.
Dr Velu said, “The new Neuberg oncopathology lab will bring synergy to distributed healthcare infrastructure through technology so that cancer diagnosis can be done at the community level and patient care becomes coordinated and seamless. The centre will leverage the capabilities of the Neuberg Centre for Genomic Medicine and spearhead cancer care delivery with a robust belief in the Whole Genome Sequencing (WGS) method to enable understanding of the Indian genomic cancer map. Further, these practices will bring in a generational shift in the way cancer care is delivered in India.”
“Oncopathologists play an essential role by testing tumour samples with various techniques to diagnose cancer and its pathological stage. This would further impact the modality and outcome of treatment and the quality of the patient’s life, post-treatment. And we are delighted to have one of the country’s leading experts, Dr Jay Mehta, as a part of our team,” added Dr Velu.
Dr Mehta said, “Oncopathology is one of the niche branches of medicine that relates to the diagnosis of cancer through an array of tests carried out on patient’s tumour samples. The newly established laboratory is a second opinion reference laboratory spread over 10,000 square feet and will provide end-to-end reports from Histopathology to Molecular tests which impact precision medicine and personalised cancer treatment. The laboratory is well equipped, with the potential to provide testing of cases from across the county.”
“Neuberg Oncopathology laboratory adds to the list of limited end-to-end Oncopathology services available in the country and will strive to stand out as the preferred option for medical and surgical oncologists from both government and private hospitals across the country,” added Dr Mehta.
